Recent exciting findings on apoptosis indicate that both neuronal selection during embryonic development and some forms of neuronal death in adults are regulated by members of the B cell leukemia-2 (Bcl-2) family such as Bcl-2, Bcl-x and Bax (1). Bcl-2 prevents apoptotic death in neurons and several neuron-like cell lines (1) . In con trast, Bax promotes apoptosis, probably due to an abil ity to form heterodimers with Bcl-2 or Bcl-x (2).
The human neuroblastoma cell line SH-SY5Y was sub cloned from the SK-N-SH cell line (3). SH-SY5Y cells are often used as a model of human neuronal cells and has been extensively used in the study of neuronal function (4). Recently, it is reported that high levels of Bcl-2 are expressed in SH-SY5Y cells (5). However, the details of the regulatory mechanisms of Bcl-2 protein expression in human neuronal cells are yet unknown. Recently, we de termined that Bcl-2 expression was regulated positively by protein kinase C and negatively by protein kinase A (6). In the present study, we further examined the effects of inhibitors for protein phosphatases, tyrosine kinases and phosphatidylinositol (PI) 3-kinase on the expression of Bcl-2 or Bcl-x in human neuroblastoma SH-SY5Y cells.
Mouse plemented with 10% (v/v) fetal calf serum and 50 pg/ml of penicillin and 100 pg/ml of streptomycin and were kept at 37V in humidified 5 % CO2 / 95% air. The SH SY5Y cells were treated for 4 days with okadaic acid (at 10 pM 3 nM), rapamycin (at 30 nM 3 pM), cyclosporin A (at 0.3 ,uM -10 pM), FK506 (at 0.3 pM 3 pM), wort mannin (at 1 nM 10 pM), herbimycin A (at 1.74 pM), PDGF-BB (at 3.3 nM), or PMA (at 10 nM). After treat ment, cells were rinsed with phosphate-buffered saline and then were scraped and lysed. Subsequently, cell ly sates were subjected to immunoblot analysis.
The cell lysate sample (10,ug protein) was dissolved in Laemmli's sample buffer and subjected to SDS-PAGE (14% polyacrylamide gels) (7). Western blotting was performed by transferring proteins from a slab gel to a sheet of polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Richmond, CA, USA) by electroelution at a constant voltage of 50 V for 2 hr at 4°C. After the PVDF membrane was incubated with Tris-buffered saline (pH 8.0) containing 0.05016 Tween-20 (TBS-T) and 5016 de hydrated skim milk (Difco, Detroit, MI, USA) to block nonspecific protein binding, the membrane was incubated with primary antibodies such as mouse anti-Bcl-2 anti body (diluted 1 : 300) or rabbit antibodies against Bcl-x (1 : 125) and Bax (diluted 1 : 300), and secondary anti body (horseradish peroxidase-linked antibodies against mouse immunoglobulin, diluted 1 : 1500). Subsequently, membrane-bound horseradish peroxidase-labeled anti bodies were detected by the ECL system (ECL kit). The protein bands that cross-reacted with antibodies could be detected on X-ray films (X-Omat JB-1; Kodak, Rochester, NY, USA) 5 30 sec after the exposure. The bands of Bcl-2 and Bcl-x on X-ray films were scanned and densitometrically analyzed by a dual-wavelength flying spot scanner (CS-9000; Shimadzu, Kyoto). Statistical differences were analyzed by Student's t-test. Prestained SDS-PAGE standards (Bio-Rad) were used as molecular weight markers. Apparent molecular weights of phospho rylase B, bovine serum albumin, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor and lysozyme were 105, 82, 49, 33.3, 28.6 and 19.4 kDa, respectively, ac cording to the manufacturer's instructions.
In SH-SY5Y cells, anti-Bcl-2 antibody immunoreacted mainly with 27-kDa Bcl-2a, and this protein level was in creased by treatment of rapamycin or PMA (Fig. IA) . In addition, these enhancements were necessary for treat ments of over 2 days (data not shown). Although the 55 kDa protein also immunoreacted with anti-Bcl-2 anti body, this protein level was not changed by any reagents used in this study (Fig. IA) . Therefore, we examined changes in the protein level of 27-kDa Bcl-2a by treat ment with several reagents for 4 days. Table 1 shows effects of reagents used in the present study. Although cell toxicity occurred with over 10 nM of okadaic acid, treat ments with other reagents at the concentrations used in this study did not cause morphological changes (data not shown). Okadaic acid is the most potent among reagents used in the present study. Briefly, treatment with okadaic acid for 4 days enhanced the Bcl-2 level in a concentration-depend ent manner (EC50 value, 1.8 nM; maximal activity, 422%). Among the other reagents, rapamycin has more potency to enhance the Bcl-2 level ( Fig. 2A) . Although cyclosporin A and FK506 tended to enhance the Bcl-2 level, these enhancements were not significant. EC50
values of rapamycin and wortmannin were 0.11 pM and 1.7 ,uM, respectively ( Fig. 2A) . Herbimycin A at 1 pg/ml (1.74 ,uM) also enhanced it significantly (Table 1) . On the other hand, PDGF-BB at 100 ng/ml (3.3 nM) inhibited Bcl-2 level significantly (Table 1) .
We further examined effects of PMA and rapamycin on Bcl-x expression. Anti-Bcl-x antibody specifically im munoreacted with a doublet of 29/30-kDa Bcl-xL in SH SYSY cells (Fig. 1B) . Treatment with PMA at 10 nM for 4 days significantly enhanced Bcl-xL level, although treat ment with rapamycin at 3 pM did not (Fig. 2B) . On the other hand, treatment for 4 days with PMA at 10 nM or rapamycin at 3 pM did not significantly change the pro tein level of 21-kDa Bax (data not shown).
Previously, we determined that Bcl-2 expression was regulated positively by protein kinase C and negatively by protein kinase A (6). In the present study, since treatment with okadaic acid, a potent inhibitor for protein phos phatases 1 and 2A (8), induced most enhancement of Bcl 2 level, the dephosphorylation by protein phosphatase 1 or 2A also plays key role in the maintenance of Bcl-2 protein level in SH-SY5Y cells. Protein phosphatase 2B (calcineurin) is known as another protein phosphatase and is inhibited by several immunosuppressants such as FK506 and cyclosporin A (9). In brief, FK506 and cyclosporin A bind to FK506 binding proteins (FKBP) or cyclophillins and then inhibit the phosphatase activity of calcineurin (9). Rapamycin also can bind to FKBP, but does not inhibit calcineurin. Recently, several papers described that FK506 and cyclo sporin A induced enhancement of Bcl-2 expression but rapamycin and okadaic acid did not in human Burkitt's lymphoma (BL) cell line (10) and that interleukin-2 induced Bcl-2 expression was inhibited by rapamycin but was not by FK506 in murine bone marrow-derived pro-B (F7) cell line (11). In the present study, however, More recent papers suggest that the complex of FKBP and rapamycin further binds to FKBP-rapamycin-as sociated protein (FRAP) (12) and then inhibits p70 S6 kinase (13). In addition, PDGF-BB-dependent p70 S6 kinase activation is mediated by activation of PI 3-kinase (14) and protein kinase B (c-Akt) (15). In the present study, both the tyrosine kinase inhibitor herbimycin A and the PI 3-kinase inhibitor wortmannin also enhanced the Bcl-2 level, but PDGF-BB decreased it. From these observations, we considered that the activation cascade of tyrosine kinase, PI 3-kinase and p70 S6-kinase further regulates Bcl-2 expression in SH-SY5Y cells. On the other hand, PMA-treatment induced enhancement of both Bcl 2a and Bcl-xL levels. However, rapamycin-treatment did not change the Bcl-xL level. Thus, expression mecha nisms of Bcl-2 and Bcl-x seem to be different in SH-SY5Y cells.
In conclusion, the present study suggests that main tenance of Bcl-2 protein level is regulated by protein phosphatase 1 or 2A. In addition, the activation cascade of p70 S6-kinase is also possibly involved in negative regulation of Bcl-2 expression in human neuroblastoma cells. On the other hand, Bcl-x expression was differently regulated than Bcl-2 expression.
